PMID- 12534356
OWN - NLM
STAT- MEDLINE
DCOM- 20030224
LR  - 20190906
IS  - 0804-4643 (Print)
IS  - 0804-4643 (Linking)
VI  - 148
IP  - 1
DP  - 2003 Jan
TI  - Plasma chromogranin A in patients with sporadic gastro-entero-pancreatic 
      neuroendocrine tumors or multiple endocrine neoplasia type 1.
PG  - 39-43
AB  - OBJECTIVE: As circulating chromogranin A (CgA) has been claimed to be the best 
      general neuroendocrine marker so far available, we evaluated the usefulness of 
      CgA determination in the clinical assessment of patients with sporadic 
      gastro-entero-pancreatic neuroendocrine tumors (GEP NETs) or multiple endocrine 
      neoplasia type 1 (MEN 1). DESIGN AND METHODS: Plasma CgA levels were measured 
      using a commercial enzyme-linked immunosorbent assay in 61 patients with sporadic 
      GEP NET and in 25 with MEN 1 including 16 with GEP NET. Controls were 50 healthy 
      volunteers, 46 patients with pituitary adenoma and 35 patients with primary 
      hyperparathyroidism. RESULTS: The cutoff value for CgA established in our healthy 
      subjects (as mean+2 s.d.) was 20 U/l. CgA levels were above the normal range in 
      71/77 patients with sporadic or MEN 1-related GEP NETs (92%), in four out of nine 
      MEN 1 patients without GEP NETs (44%), and only in 22/81 control patients with 
      pituitary or parathyroid disease (27%). Furthermore, CgA levels of over 100 U/l 
      occurred in 36/77 patients with GEP NETs (47%) and only in one patient with a 
      non-functioning pituitary adenoma. In the patients with GEP NETs, both tumor 
      burden and secretory activity affected CgA levels, and successful surgical 
      resection was associated with markedly decreased CgA values. CONCLUSIONS: Plasma 
      CgA was confirmed to be a reliable marker for GEP NETs. Moreover, in MEN 1 
      patients the finding of very high CgA levels strongly suggests the presence of a 
      GEP NET, as both primary hyperparathyroidism and pituitary adenomas rarely cause 
      marked CgA increases.
FAU - Peracchi, M
AU  - Peracchi M
AD  - Institute of Endocrine Sciences, University of Milan, Ospedale Maggiore IRCCS, 
      Padiglione Granelli, Via F Sforza 35, 20122, Milan, Italy. 
      maddalena.peracchi@unimi.it
FAU - Conte, D
AU  - Conte D
FAU - Gebbia, C
AU  - Gebbia C
FAU - Penati, C
AU  - Penati C
FAU - Pizzinelli, S
AU  - Pizzinelli S
FAU - Arosio, M
AU  - Arosio M
FAU - Corbetta, S
AU  - Corbetta S
FAU - Spada, A
AU  - Spada A
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Eur J Endocrinol
JT  - European journal of endocrinology
JID - 9423848
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (CHGA protein, human)
RN  - 0 (Chromogranin A)
RN  - 0 (Chromogranins)
SB  - IM
MH  - Adenoma/blood/diagnosis
MH  - Adult
MH  - Aged
MH  - Biomarkers, Tumor/*blood
MH  - Chromogranin A
MH  - Chromogranins/*blood
MH  - Female
MH  - Gastrinoma/blood/diagnosis
MH  - Humans
MH  - Insulinoma/blood/diagnosis
MH  - Intestinal Neoplasms/blood/diagnosis
MH  - Male
MH  - Middle Aged
MH  - Multiple Endocrine Neoplasia Type 1/*blood/*diagnosis
MH  - Pancreatic Neoplasms/blood/diagnosis
MH  - Pituitary Neoplasms/blood/diagnosis
MH  - Sensitivity and Specificity
MH  - Stomach Neoplasms/blood/diagnosis
EDAT- 2003/01/22 04:00
MHDA- 2003/02/25 04:00
CRDT- 2003/01/22 04:00
PHST- 2003/01/22 04:00 [pubmed]
PHST- 2003/02/25 04:00 [medline]
PHST- 2003/01/22 04:00 [entrez]
AID - 10.1530/eje.0.1480039 [doi]
PST - ppublish
SO  - Eur J Endocrinol. 2003 Jan;148(1):39-43. doi: 10.1530/eje.0.1480039.